LONDON--(BUSINESS WIRE)--According to the latest market research study released by Technavio, the global deep brain stimulation market is expected to exceed USD 906 billion by 2020, growing at a CAGR of almost 11% during the forecast period.

This research report titled ‘Global Deep Brain Stimulation (DBS) Market 2016-2020’, provides an in-depth analysis of the market in terms of revenue and emerging market trends. This market research report also includes an up to date analysis and forecast for various market segments and all geographical regions.

Request sample report: http://goo.gl/fl5KwR
The report segments the DBS market by application and can be divided into four broad segments:

Parkinson's Disease
Dystonia
Obsessive-Compulsive Disorder
Epilepsy
Parkinson's Disease

According to the Parkinson's Disease Foundation, around 10 million people have Parkinson's Disease (PD) worldwide. DBS system is implanted in patients whose PD symptoms such as tremor, rigidity, stiffness, slow movement, and walking disability cannot be treated with medicines. For such cases, MRI scanning is done to identify the diseased area in the brain, which helps physicians to implant the electrodes that stimulate the motor neuron.

Medtronic is leading the market with its technologically advanced product lines. Vendors such as Boston Scientific developed Vercise Deep Brain Stimulation System for PD for its product expansion. “As a result of technological innovation and clinical expansion, PD occupied 76% share of the global DBS market,” says Barath Palada, lead analyst at Technavio for patient monitoring devices research.

Dystonia

Dystonia is a neurological disorder characterized by slow repetitive movements or abnormal body postures. The disease causes involuntary muscle contraction, which makes movement painful. Surgeons suggest DBS therapy when medications cannot alleviate the symptoms. Activa Dystonia Therapy Kit, Vercise Deep Brain Stimulation System, and Medtronic Deep Brain Stimulation Therapy are some of the therapies used to treat this disease.

In the US, DBS therapy for dystonia is approved under a specific condition known as Humanitarian Device Exemption as extensive clinical research is not carried out for dystonia. In European countries, Vercise Deep Brain Stimulation System, approved by Conformité Européenne (CE) in November 2013, is used for the treatment of neurological movement disorder, intractable primary and secondary dystonia, and involuntary muscle contraction. Dystonia accounted for a 10% share of the global DBS market in 2015.

Market Analysis Homepage